Search alternatives:
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
linear decrease » linear increase (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
linear decrease » linear increase (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
3041
Computational parameters used in the simulations.
Published 2025“…A combination of bench and simulation tests validated the test results, showing no significant differences and confirming the method’s viability for determining COR. …”
-
3042
Collision materials.
Published 2025“…A combination of bench and simulation tests validated the test results, showing no significant differences and confirming the method’s viability for determining COR. …”
-
3043
Diagram of displacement variation.
Published 2025“…A combination of bench and simulation tests validated the test results, showing no significant differences and confirming the method’s viability for determining COR. …”
-
3044
Scheme and results of orthogonal test.
Published 2025“…A combination of bench and simulation tests validated the test results, showing no significant differences and confirming the method’s viability for determining COR. …”
-
3045
The millet mode.
Published 2025“…A combination of bench and simulation tests validated the test results, showing no significant differences and confirming the method’s viability for determining COR. …”
-
3046
-
3047
-
3048
-
3049
-
3050
-
3051
-
3052
-
3053
-
3054
-
3055
Fecal egg count reduction percentage (FECRP).
Published 2025“…Statistically, there was a significant decrease in EPG values from days 0–14. …”
-
3056
Data Sheet 1_Patient-centered modeling of the breast biopsy experience.pdf
Published 2025“…Higher baseline stress was strongly associated with greater anxiety during biopsy. Centering each individual's procedure time at her first local anesthesia (LA) revealed a significant (βt2p = 5.43e<sup>−06</sup>) temporal pattern in anxiety, which increased until LA and decreased afterwards. …”
-
3057
Table 1_The impact of IL-17A inhibitors on scalp and gut microbiota in psoriasis.docx
Published 2025“…Moreover, the abundance of Roseburia, Megamonas, and the phylum Bacteroidota increased, although the Firmicutes/Bacteroidota (F/B) ratio showed no significant change. Conclusion: IL-17A inhibitor therapy has the potential to improve the structure and diversity of the scalp microbiome, gradually restoring it toward a healthier state while also enhancing gut microbiota diversity. …”
-
3058
Data Sheet 1_Unveiling frailty: comprehensive and sex-specific characterization in prematurely aging PolgA mice.pdf
Published 2024“…We demonstrated that frailty became evident in PolgA mice around 40 weeks, validated through body weight loss, reduced walking speed, decreased physical activity, and weaker grip strength. …”
-
3059
Image 1_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.pdf
Published 2025“…Background<p>Charged Multivesicular Body Protein 4A (CHMP4A), a member of the ESCRT-III family, plays a pivotal role in membrane remodeling and fission, with emerging evidence underscoring its significance in cancer immunotherapy. …”
-
3060
Table 1_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.docx
Published 2025“…Background<p>Charged Multivesicular Body Protein 4A (CHMP4A), a member of the ESCRT-III family, plays a pivotal role in membrane remodeling and fission, with emerging evidence underscoring its significance in cancer immunotherapy. …”